CLL Live 2015 - CLL Patient Advocacy Group (CLLPAG)
Transcription
CLL Live 2015 - CLL Patient Advocacy Group (CLLPAG)
CLL Live 2015 Recent Developments in CLL Treatments European, American and Canadian Perspectives April 23-25, 2015 Niagara Falls, Ontario – Sheraton On The Falls Hotel A conference for CLL patients, their families and caregivers presented by: Featured Speakers: Dr. Michael Hallek Dr. Spencer Gibson Keynote Speaker Chair, German CLL Study Group Professor of Medicine and Director and Chair of the Department of Internal Medicine, University of Cologne, Germany Director, Manitoba Institute of Cell Biology Professor and Manitoba Chair, Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba Dr. Michael J. Keating Dr. Graeme Fraser President and CEO, CLL Global Research Foundation Professor of Medicine, University of Texas MD Anderson Cancer Center CLL Live 2015 Medical Chair Clinical Hematologist, Juravinski Cancer Centre, Hamilton Health Sciences Associate Professor, Department of Oncology, McMaster University Evening reception on Thursday, full day of presentations on Friday including dinner program Friday evening, half day of presentations on Saturday. REGISTER Full conference schedule available on websites. www.LLSCanada.org/CLLLive or www.CLLPAG.ca Conference attendance is free of charge; hotel and travel to Niagara Falls is the responsibility of the participant. For more information call 1-877-668-8326 ext. 5509 or email [email protected] Platinum Sponsors As the conference is provided on a complimentary basis, we ask that only one caregiver attend with each patient. If there are circumstances that would require more than one caregiver to attend, please email [email protected] outlining your request.
Similar documents
Global Chronic Lymphocytic Leukemia (CLL) Market Size, Segmentation, Demand Forecast Report Up To 2015: Radiant Insights, Inc
'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015', provides an overview of the Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.
More information